Page last updated: 2024-11-05

talactoferrin alfa and Bacteremia

talactoferrin alfa has been researched along with Bacteremia in 1 studies

talactoferrin alfa: recombinant human lactoferrin, an oral drug for treatment of refractory solid tumors; in Phase I trial 5/2006

Bacteremia: The presence of viable bacteria circulating in the blood. Fever, chills, tachycardia, and tachypnea are common acute manifestations of bacteremia. The majority of cases are seen in already hospitalized patients, most of whom have underlying diseases or procedures which render their bloodstreams susceptible to invasion.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Sherman, MP1
Adamkin, DH1
Niklas, V1
Radmacher, P1
Sherman, J1
Wertheimer, F1
Petrak, K1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Phase 1/2 Study of Talactoferrin Oral Solution for Nosocomial Infection in Preterm Infants[NCT00854633]Phase 1/Phase 2120 participants (Anticipated)Interventional2009-06-30Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trials

1 trial available for talactoferrin alfa and Bacteremia

ArticleYear
Randomized Controlled Trial of Talactoferrin Oral Solution in Preterm Infants.
    The Journal of pediatrics, 2016, Volume: 175

    Topics: Administration, Oral; Bacteremia; Cross Infection; Double-Blind Method; Enterocolitis, Necrotizing;

2016